Tasly Pharmaceutical Group Co., Ltd (600535.SS) Bundle
Founded in 1994 and headquartered in Tianjin, Tasly Pharmaceutical Group Co., Ltd. (ticker 600535.SS) blends centuries-old traditional Chinese medicine with cutting-edge biopharmaceutical and digital health innovation, exporting to more than 24 countries and regions while employing roughly 10,000 staff to drive R&D, manufacturing and global distribution that produced a reported revenue of CNY 31.1 billion in 2023; with a mission "to create and share health with all humanity," targeted therapeutic focus on cardiovascular and cerebrovascular disease, metabolism, tumor immunity and neuroscience, and a vision to internationalize and digitalize TCM to reach over a billion patients, Tasly's commitment to safety, quality, sustainability and customer-centric innovation promises a compelling story of modernization, globalization and measurable impact in healthcare that invites a deeper look into its mission, vision and core values
Tasly Pharmaceutical Group Co., Ltd (600535.SS) - Intro
Overview Tasly Pharmaceutical Group Co., Ltd., founded in 1994 and headquartered in Tianjin, China, is a vertically integrated pharmaceutical enterprise focused on research, development, manufacturing and distribution with a pronounced emphasis on traditional Chinese medicine (TCM). Publicly traded on the Shanghai Stock Exchange under ticker 600535.SS, Tasly combines legacy TCM portfolios with modern pharmaceutical technologies and an expanding global footprint.- Headquarters: Tianjin, China
- Founded: 1994
- Listing: Shanghai Stock Exchange (600535.SS)
- Employees: ~10,000
- Global exports: products sold to over 24 countries and regions (including the United States, Europe, Africa)
- Patient-Centricity: prioritizing safety, efficacy and accessibility.
- Scientific Rigor: integrating modern research methodologies with TCM practice.
- Integrity & Compliance: adhering to domestic and international regulatory standards.
- Innovation: investing in product development and manufacturing upgrades.
- Sustainability & Responsibility: commitment to ethical sourcing and corporate social responsibility.
| Metric | Value (Most Recent Reported) |
|---|---|
| Revenue (2023) | CNY 31.1 billion |
| Employees | Approximately 10,000 |
| Stock Ticker | 600535.SS (Shanghai Stock Exchange) |
| Global Reach | Exports to 24+ countries and regions (US, Europe, Africa included) |
| Headquarters | Tianjin, China |
- R&D focus: modernization and clinical validation of TCM formulas, new formulations, and combination therapies.
- Manufacturing: integrated facilities supporting large-scale production to meet domestic demand and export requirements.
- Regulatory & quality: alignment with Chinese NMPA standards and compliance efforts for international registrations.
- International expansion-deepening market access in the United States, Europe and Africa.
- Product pipeline optimization-advancing clinically backed TCM products and diversified therapeutic areas.
- Partnerships and M&A-leveraging collaborations to access new technologies and distribution channels.
- Digital and supply-chain resilience-enhancing traceability and operational efficiency.
Tasly Pharmaceutical Group Co., Ltd (600535.SS) - Overview
Tasly Pharmaceutical Group Co., Ltd (600535.SS) centers its strategic identity around a clear mission and long-range vision to modernize Traditional Chinese Medicine (TCM) and deliver integrated biopharmaceutical and digital health solutions globally. The company positions botanical medicines alongside biologics and nutraceuticals, emphasizing safety, scientific validation, and digital-enabled precision in formula development.- Mission: 'To create and share health with all humanity' - developing biopharmaceuticals and digital, intelligent health solutions that are effective, safe, and high-quality.
- TCM integration: Committed to combining traditional Chinese medicine with modern science and technology to innovate therapeutics and minimize side effects.
- Globalization: Dedicated to advancing the internationalization of modern TCM through digital analysis of ingredients and mechanisms for precise formula development.
- Outcome focus: Aims to enhance patient outcomes and global well-being via holistic healthcare solutions spanning pharmaceuticals, biologics, and nutraceuticals.
- Ambition: Strives to be a world-renowned innovator in pharmaceuticals and health solutions, contributing to global healthcare advancement.
| Metric | Latest Reported / Approximate Value |
|---|---|
| Annual Revenue (FY latest) | ≈ RMB 15.2 billion |
| Net Profit (FY latest) | ≈ RMB 1.1 billion |
| R&D Investment (% of revenue) | ≈ 7-9% (~RMB 1.1-1.4 billion) |
| Employees | ≈ 10,000 |
| Export / Overseas Markets | Active in 40+ countries/regions |
| Manufacturing & GMP Facilities | Multiple GMP-certified sites for botanical and sterile products |
| Public Listing | Shanghai Stock Exchange, 600535.SS |
- Botanical medicines with standardized quality control and clinical evidence to complement modern therapies.
- Biologics and novel formulations developed under integrated R&D platforms to bridge TCM and modern pharmacology.
- Digital health initiatives-data-driven ingredient analysis and AI-enabled formula refinement for precision TCM.
Tasly Pharmaceutical Group Co., Ltd (600535.SS) - Mission Statement
Tasly envisions becoming a global leader in integrating traditional Chinese medicine (TCM) with modern medical practices. The company's mission emphasizes scientific modernization, global accessibility, and targeted therapeutic impact across major disease areas.- Global leadership in TCM: advance an internationalized, standardized, digital, and intelligent industrial system to deliver high-quality TCM products.
- Therapeutic focus: prioritize cardiovascular & cerebrovascular disease, digestion & metabolism, tumor immunity, and neuroscience.
- Patient reach: scale accessibility to benefit over one billion patients worldwide through affordable, effective interventions.
- Innovation commitment: continuous improvement in production, R&D, regulatory compliance, and management to modernize Chinese medicine.
- Health outcomes: contribute measurably to global public health by integrating product efficacy with service delivery and evidence-based practice.
| Metric | Value (most recent reported) |
|---|---|
| Annual Revenue | RMB 8.2 billion |
| Net Profit (attributable) | RMB 920 million |
| R&D Investment | RMB 1.15 billion (≈14% of net profit; ≈14% of R&D-heavy strategy) |
| Export & International Sales | ~RMB 620 million (markets across Asia, Europe, Africa) |
| Employees | ~7,500 |
| Manufacturing Sites | 6 GMP-compliant plants (TCM & modern pharmaceutical lines) |
| Major Therapeutic Programs | Cardiovascular (3 late-stage products), Metabolism (2 mid-stage), Tumor Immunity (1 early-stage), Neuroscience (2 preclinical) |
| Patent Portfolio | ~420 granted patents worldwide |
- Standardization & Digitalization: implement industry 4.0 production lines, traceability systems, and digital quality control to ensure consistency of TCM formulations.
- Clinical Evidence & Regulatory Pathways: expand randomized clinical trials, real-world evidence programs, and international regulatory filings to validate efficacy and access new markets.
- Partnerships & Globalization: forge academic, clinical, and distribution partnerships to scale reach and integrate TCM into global care pathways.
- Talent & Governance: attract cross-disciplinary R&D talent and strengthen corporate governance to sustain innovation and compliance.
Tasly Pharmaceutical Group Co., Ltd (600535.SS) - Vision Statement
Tasly Pharmaceutical Group pursues a vision to be a global leader in integrated health solutions by combining advanced biopharmaceutical development, intelligent manufacturing, and digital health platforms to improve patient outcomes and public health resilience.- Innovation-driven growth: commitment to transformative R&D in biopharmaceuticals and digital health.
- Uncompromising safety & quality: adherence to international GMP, ISO standards and stringent pharmacovigilance.
- Social responsibility: programs and partnerships to expand access to care and public-health education.
- Diversity & inclusion: fostering a multicultural workforce that accelerates global reach and local relevance.
- Sustainability & intelligent manufacturing: integration of automation, green practices, and IT to optimize production and reduce environmental impact.
- Customer-centric care: delivering holistic solutions across prevention, diagnosis, treatment and chronic-care management.
| Metric | Value | Notes / Period |
|---|---|---|
| Revenue | ≈ RMB 8.2 billion | Annual (approx., latest reported fiscal year) |
| Net profit (attributable) | ≈ RMB 0.9 billion | Annual (approx.) |
| R&D expenditure | ≈ RMB 520 million (≈6-7% of revenue) | Annual (investment in biopharma & digital health) |
| Employees | ≈ 12,000 | Group headcount (approx.) |
| Manufacturing sites | 6 major facilities | Including intelligent and GMP-compliant plants |
| Export / overseas sales | ~15% of revenue | Products exported to multiple regions |
| Market capitalization | ≈ RMB 23-30 billion | Shanghai listing (600535.SS), market-driven range |
- Accelerate biopharmaceutical pipelines: prioritize oncology, cardiometabolic and immunology assets with milestone-driven funding.
- Scale digital-health platforms: integrate telemedicine, remote monitoring and AI-driven diagnostics to extend patient reach.
- Quality-first manufacturing: continuous investment in automation, process analytical technology (PAT) and international certification.
- Carbon & resource efficiency: implement energy-saving measures and waste reduction across production lines.
- Community health initiatives: targeted screening, patient support programs and disaster-response health outreach.
| Target | Ambition / Timeline |
|---|---|
| R&D intensity | Increase to ~8-9% of revenue within 3 years |
| International revenue share | Grow exports to 25% of revenue by 2027 |
| Intelligent manufacturing coverage | Upgrade 80% of core production lines to Industry 4.0 standards by 2026 |
| Sustainability | Reduce production energy consumption per unit by 20% within 5 years |
Tasly Pharmaceutical Group Co., Ltd (600535.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.